Nanoparticles in Targeted Alpha Therapy

Recent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery. In this publication, we provide a comprehensive overview of available information on functional nanomaterials for targeted alpha therapy. The first section describes why nanoconstructs are used for the synthesis of α-emitting radiopharmaceuticals. Next, we present the synthesis and summarise the recent studies demonstrating therapeutic applications of α-emitting labelled radiobioconjugates in targeted therapy. Finally, future prospects and the emerging possibility of therapeutic application of radiolabelled nanomaterials are discussed.

Download Full-text

Future Prospects for Targeted Alpha Therapy

Current Radiopharmaceuticals ◽

10.2174/1874471011104040336 ◽

2011 ◽

Vol 4 (4) ◽

pp. 336-342 ◽

Cited By ~ 7

Author(s):

Barry J. Allen

Keyword(s):

Future Prospects ◽

Targeted Alpha Therapy ◽

Alpha Therapy

Download Full-text

Nanotechnology Based Targeted Drug Delivery: Current Status and Future Prospects for Drug Development

Drug Discovery and Development - Present and Future ◽

10.5772/28902 ◽

2011 ◽

Cited By ~ 1

Author(s):

Sadhna Sharma ◽

Amandeep Singh

Keyword(s):

Drug Delivery ◽

Drug Development ◽

Targeted Drug Delivery ◽

Current Status ◽

Future Prospects ◽

Targeted Drug

Download Full-text

Biomedical Applications of Targeted Drug Delivery, Nanotheranostic and Nuclear Medicine

10.20944/preprints202105.0643.v1 ◽

2021 ◽

Author(s):

Idris Sadiq ◽

Fatima Sadiq Abubakar ◽

Hassan Aliyu Hassan

Keyword(s):

Drug Delivery ◽

Nuclear Medicine ◽

Targeted Drug Delivery ◽

Biomedical Applications ◽

Inorganic Nanoparticles ◽

Radioactive Isotopes ◽

Target Tissue ◽

Systemic Distribution ◽

Novel Method ◽

Targeted Drug

Background: Convectional methods for drug delivery often faces setbacks due to systemic distribution, short half-life and degradation of therapeutics and therefore reduce concentrations of drug available to target tissue. Nanotheranostic provide a novel method for treating and diagnosing diseases Methodology: collection and review of relevant literatureResult: while nanotheranostic offer advantage of personalized medicine and often combines diagnosis and therapy using single molecular approach, nuclear medicine relies on radioactive isotopes to diagnosed and destroys cancer cells. In both cases, nanocarriers such as lipid-based, polymer-based, drug-conjugate, inorganic nanoparticles are used to deliver drugs/probes/isotopes to target site, generating images and thereafter chemotherapy/radiotherapy begins.Conclusion: Nanotheranostic plays important role in diseases diagnostic, therapy, imaging, monitoring of disease progression / response through the use of nanocarriers. This is made possible through nanoparticles/nanocarriers that delivers drug to the target tissues/cells.

Download Full-text

Individual dosimetry system for targeted alpha therapy based on PHITS coupled with microdosimetric kinetic model

EJNMMI Physics ◽

10.1186/s40658-020-00350-7 ◽

2021 ◽

Vol 8 (1) ◽

Author(s):

Tatsuhiko Sato ◽

Takuya Furuta ◽

Yuwei Liu ◽

Sadahiro Naka ◽

Shushi Nagamori ◽

...

Keyword(s):

Nuclear Medicine ◽

Kinetic Model ◽

Ct Images ◽

Source Distribution ◽

Organ Doses ◽

Targeted Alpha Therapy ◽

Pet Ct ◽

Individual Dosimetry ◽

Dosimetry System ◽

Alpha Therapy

Abstract Background An individual dosimetry system is essential for the evaluation of precise doses in nuclear medicine. The purpose of this study was to develop a system for calculating not only absorbed doses but also EQDX(α/β) from the PET-CT images of patients for targeted alpha therapy (TAT), considering the dose dependence of the relative biological effectiveness, the dose-rate effect, and the dose heterogeneity. Methods A general-purpose Monte Carlo particle transport code PHITS was employed as the dose calculation engine in the system, while the microdosimetric kinetic model was used for converting the absorbed dose to EQDX(α/β). PHITS input files for describing the geometry and source distribution of a patient are automatically created from PET-CT images, using newly developed modules of the radiotherapy package based on PHITS (RT-PHITS). We examined the performance of the system by calculating several organ doses using the PET-CT images of four healthy volunteers after injecting 18F-NKO-035. Results The deposition energy map obtained from our system seems to be a blurred image of the corresponding PET data because annihilation γ-rays deposit their energies rather far from the source location. The calculated organ doses agree with the corresponding data obtained from OLINDA 2.0 within 20%, indicating the reliability of our developed system. Test calculations by replacing the labeled radionuclide from 18F to 211At suggest that large dose heterogeneity in a target volume is expected in TAT, resulting in a significant decrease of EQDX(α/β) for higher-activity injection. Conclusions As an extension of RT-PHITS, an individual dosimetry system for nuclear medicine was developed based on PHITS coupled with the microdosimetric kinetic model. It enables us to predict the therapeutic and side effects of TAT based on the clinical data largely available from conventional external radiotherapy.

Download Full-text